Higher doses of upadacitinib show added benefits for adults with moderate-to-severe AD when compared to dupilumab, according to a new study.

According to a new study, adults with AD have a higher incidence of systemic, autoimmune, and psychiatric comorbidities than those without.

Patients being treated with dupilumab for atopic dermatitis may experience less severe Covid-19 symptoms, according to a new study.

Research has suggested that intrauterine mechanisms of overweight women in pre-pregnancy may have increased risks of their infant having AD.

Researchers have linked a key protein called TWEAK to inflammation in psoriasis patients.

A new study tested risankizumab in patients with severe asthma and found it worsened their asthma symptoms.

Researchers have surveyed 137 respondents from a psoriatic arthritis registry for characteristics, therapies and medication preference.

Results of a phase 3 trial have linked dupilumab to significantly reduced skin lesions and itch when compared to placebo.